Germany· DE-A57-67eabec035891784
Adrimedac
A doxorubicin product containing doxorubicin hydrochloride, registered in Germany by Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel). The same ATC class is registered in 17 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Doxorubicin is registered in 17 of 19 countries.
Countries holding a registration under ATC L01DB01 (doxorubicin), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Doxorubicin · ATC L01DB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of doxorubicin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Doxorubicin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$12.19
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Doxorubicin Hydrochloride
- Manufacturer
- Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
- Country
- Germany (DE)
- ATC code
- L01DB01
- ATC class
- Doxorubicin
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- August 5, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
775 interactions on record for doxorubicin.
Graded by severity as the source publishes them — 98 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Doxorubicin · interactions on record
775 records
- 98 severe
- 383 moderate
- 29 minor
- 265 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Doxorubicin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDOXILBaxter Healthcare Corporation
- United KingdomCaelyx 20mg/10ml concentrate for solution for infusion vialsJanssen-Cilag Ltd
- BelgiumAdriblastina 10 10 mgPfizer
- CzechiaCAELYX PEGYLATED LIPOSOMALBaxter Holding B.V., Utrecht
- SwitzerlandAdriblastin RD
- FinlandAdriamycinPfizer Oy
- SpainCAELYX PEGYLATED LIPOSOMAL 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBaxter Holding B.V.
- FranceADRIBLASTINE 10 mg, poudre pour solution injectable en flaconPFIZER HOLDING FRANCE
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Adriblastin, Doxorubicin Accord
- Belgium · Adriblastina Ready To Use, Doxorubicin Accord Healthcare
- Bulgaria · Доксорубицин Акорд
- Cyprus · Adriblastina
- Czechia · Doxorubicin Ebewe, Doxorubicin Medac
- Denmark · Adriamycin, Doxorubicin Accord
- Estonia · Doxorubicin Accord
- Spain · Doxorubicina Accord, Doxorubicina Aurovitas
- Finland · Doxorubicin Accord, Doxorubicin Medac
- France · Adriblastine, Doxorubicin Teva
- United Kingdom (Northern Ireland) · Doxorubicin Accord Healthcare, Doxorubicin Hydrochloride Medac
- Greece · Adriblastina, Doxiprol
- Croatia · Doxorubicin Pliva, Sindroxocin
- Hungary · Doxorubicin Accord, Doxorubicin Sandoz
- Ireland · Doxorubicin Accord Healthcare Ireland, Doxorubicin Rivopharm
- Iceland · Caelyx Pegylated Liposomal, Doxorubicin Medac
- Italy · Adriblastina, Doxorubicin Teva
- Liechtenstein · Caelyx Pegylated Liposomal, Myocet Liposomal
- Lithuania · Doxorubicin Accord, Doxorubicin Ebewe
- Luxembourg · Adriblastina Ready To Use, Doxorubicine Teva
- Latvia · Doxorubicin Accord
- Malta · Doxorubicin Accord Healthcare
- Netherlands · Doxorubicin Hydrochloride Eugia, Doxorubicine Accord
- Norway · Adriamycin, Caelyx Pegylated Liposomal
- Poland · Doxorubicin Ebewe, Doxorubicinum Accord
- Portugal · Doxorrubicina Accord, Doxorrubicina Aurovitas
- Romania · Doxlox, Doxorubicină Accord
- Sweden · Doxorubicin Accord, Doxorubicin Ebewe
- Slovenia · Doksorubicin Accord, Doksorubicin Sandoz
- Slovakia · Doxorubicin Medac, Doxorubicin Sandoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7c4ea28d-94f4-4a0d-b190-0fce173ea710 GET /v1/drugs/7c4ea28d-94f4-4a0d-b190-0fce173ea710?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use, Intravesical Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Doxorubicin Hydrochloride",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about doxorubicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.